Early quality-of-life and psychological predictors of disease-free time and survival in localized prostate cancer.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Mar 2019
Historique:
accepted: 22 11 2018
pubmed: 5 12 2018
medline: 4 4 2019
entrez: 5 12 2018
Statut: ppublish

Résumé

The constructs evaluated in investigating association between psychosocial factors and cancer survival has varied between studies, and factors related to quality of life (QOL) have shown contradictory results. We investigated the effect of socioeconomic and early QOL and psychological factors on disease-free time and survival in localized prostate cancer. A consecutive sample of patients with localized prostate cancer (T1-3, N0, M0) treated with external beam radiotherapy completed validated questionnaires on coping with cancer (the Ways of Coping Questionnaire WOC-CA), anger expression (the Anger Expression Scale), life events (the Life Experience Survey), and various aspects of QOL (the Rotterdam Symptom Checklist, the Depression Scale DEPS, the EORTC QLQ-C30, the LENT-SOMA outcome measure) approximately 4.5 months after diagnosis. Cox regression analyses were used to determine the predictors of the disease-free and overall survival times measured from the date of diagnosis to the date of a PSA-relapse and date of death. After controlling for biological prognostic factors, age, and adjuvant hormonal therapies, moderate and high socioeconomic status and an increased level of pain predicted longer survival, whereas an increased level of prostate-area symptoms and fatigue and, especially, reports of no/few physical symptoms were predictors of a shorter survival time. A longer PSA-relapse-free time was predicted by Cognitive Avoidance/Denial coping, whereas problems in social functioning, hopelessness, and an excellent self-reported QOL predicted a shorter PSA-relapse-free time. Higher socioeconomic status was prognostic for longer survival, as previously reported. Patients with a seemingly good QOL (few physical complaints, excellent self-reported QOL) had poorer prognoses. This association may due to the survival decreasing effect of emotional non-expression; patients with high emotional non-expression may over-report their wellbeing in simple measures, and thus actually be in need of extra attention and care.

Identifiants

pubmed: 30511254
doi: 10.1007/s11136-018-2069-z
pii: 10.1007/s11136-018-2069-z
pmc: PMC6394517
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

677-686

Subventions

Organisme : Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital
ID : 9U020

Références

Psychiatry Res. 1999 Jan 18;85(1):51-61
pubmed: 10195316
Lancet. 1999 Oct 16;354(9187):1331-6
pubmed: 10533861
J Clin Oncol. 1999 Jul;17(7):2256-63
pubmed: 10561283
Eur J Cancer. 1999 Oct;35(11):1554-8
pubmed: 10673961
Ann Oncol. 2000 Apr;11(4):469-74
pubmed: 10847468
Br J Cancer. 2000 Dec;83(11):1448-53
pubmed: 11076652
Am J Epidemiol. 2000 Nov 15;152(10):940-9
pubmed: 11092436
Psychosom Med. 2001 May-Jun;63(3):344-51
pubmed: 11386308
BMJ. 2002 Nov 9;325(7372):1066
pubmed: 12424165
Soc Sci Med. 2004 Apr;58(8):1511-22
pubmed: 14759694
Clin Psychol Rev. 2004 Jul;24(3):315-38
pubmed: 15245834
J Psychosom Res. 2005 Jan;58(1):19-27
pubmed: 15771866
Ann Oncol. 2005 May;16(5):805-16
pubmed: 15817599
Health Psychol. 1992;11(2):79-87
pubmed: 1582383
BMJ. 1992 Apr 25;304(6834):1078-81
pubmed: 1586819
Gynecol Oncol. 2005 Jun;97(3):879-86
pubmed: 15894367
Br J Cancer. 2005 Jun 6;92(11):2089-94
pubmed: 15900301
Ann Oncol. 2006 Jan;17(1):5-19
pubmed: 16143594
Br J Cancer. 2006 May 8;94(9):1245-52
pubmed: 16670704
Psychosomatics. 2007 May-Jun;48(3):211-6
pubmed: 17478589
J Urol. 2007 Jun;177(6):1992-9
pubmed: 17509278
J Psychosom Res. 2007 Jul;63(1):9-15
pubmed: 17586333
Nat Clin Pract Oncol. 2008 Aug;5(8):466-75
pubmed: 18493231
J Clin Oncol. 2009 Jan 1;27(1):146-9
pubmed: 19047303
Urology. 2008 Dec;72(6 Suppl):S3-11
pubmed: 19095126
Urology. 2009 Mar;73(3):624-30
pubmed: 19167034
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Cancer. 2009 Nov 15;115(22):5349-61
pubmed: 19753617
J Psychosom Res. 2009 Nov;67(5):403-15
pubmed: 19837203
Psychol Med. 2010 Nov;40(11):1797-810
pubmed: 20085667
Br J Cancer. 2010 Sep 28;103(7):1109-14
pubmed: 20717112
Urology. 2010 Dec;76(6):1409-13
pubmed: 20888034
Psychother Psychosom. 2012;81(3):191-3
pubmed: 22433748
Br J Cancer. 1990 Dec;62(6):1034-8
pubmed: 2257209
J Med Screen. 2013 Mar;20(1):33-8
pubmed: 23390203
Br J Cancer. 2013 May 28;108(10):1971-7
pubmed: 23674085
Lancet. 2014 Dec 6;384(9959):2027-35
pubmed: 25108889
Soc Sci Med. 1989;28(12):1239-48
pubmed: 2660280
Br J Cancer. 2017 Mar 28;116(7):864-873
pubmed: 28222069
Cancer Surv. 1987;6(3):545-67
pubmed: 3326661
J Pers Soc Psychol. 1986 Mar;50(3):571-9
pubmed: 3701593
J Pers Soc Psychol. 1986 May;50(5):992-1003
pubmed: 3712234
J Consult Clin Psychol. 1978 Oct;46(5):932-46
pubmed: 701572
Radiother Oncol. 1995 Apr;35(1):9-10
pubmed: 7569016
Psychosom Med. 1993 May-Jun;55(3):234-47
pubmed: 8346332
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Health Psychol. 1993 Jan;12(1):16-23
pubmed: 8462494
Acta Psychiatr Scand. 1996 Jun;93(6):427-33
pubmed: 8831858
Psychosom Med. 1996 Mar-Apr;58(2):113-21
pubmed: 8849626
Lancet. 1979 Oct 13;2(8146):785-7
pubmed: 90871
Prev Med. 1997 Sep-Oct;26(5 Pt 1):623-32
pubmed: 9327469
J Natl Cancer Inst. 1998 May 20;90(10):766-71
pubmed: 9605647

Auteurs

Ulla-Sisko Lehto (US)

Medical School, Oncology, University of Tampere, 33014, Tampere, Finland. ulla-sisko.lehto@thl.fi.
Public Health Evaluation and Projection, National Institute for Health and Welfare THL, Mannerheimintie 166, P.O. Box 30, 00271, Helsinki, Finland. ulla-sisko.lehto@thl.fi.
Department of Oncology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland. ulla-sisko.lehto@thl.fi.

Markku Ojanen (M)

Department of Psychology, University of Tampere, 33014, Tampere, Finland.

Anna Väkevä (A)

Medical School, Oncology, University of Tampere, 33014, Tampere, Finland.
Department of Oncology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.

Tadeusz Dyba (T)

Finnish Cancer Registry, Pieni Roobertinkatu 9, 00130, Helsinki, Finland.
Joint Research Centre (JRC), European Commission, Building 58A/006, Via Enrico Fermi 2749, TP 581, 21027, Ispra, Italy.

Arpo Aromaa (A)

Public Health Evaluation and Projection, National Institute for Health and Welfare THL, Mannerheimintie 166, P.O. Box 30, 00271, Helsinki, Finland.

Pirkko Kellokumpu-Lehtinen (P)

Medical School, Oncology, University of Tampere, 33014, Tampere, Finland.
Department of Oncology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH